ZUBSOLV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZUBSOLV (ZUBSOLV).
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist. Naloxone is a mu-opioid receptor antagonist that is added to deter intravenous abuse by precipitating withdrawal in opioid-dependent individuals. The combination provides analgesic effects and reduces opioid withdrawal symptoms.
| Metabolism | Buprenorphine is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C8 to norbuprenorphine. Naloxone is metabolized by glucuronidation and other pathways. |
| Excretion | Buprenorphine metabolites are primarily excreted in feces (approximately 70%) via biliary elimination, with about 30% excreted in urine as unchanged drug and metabolites. Naloxone is extensively metabolized in the liver and excreted in urine (approximately 70% as metabolites) and feces (approximately 30%). |
| Half-life | Buprenorphine has a terminal elimination half-life of 24-42 hours (mean ~37 hours) due to slow dissociation from mu-opioid receptors and enterohepatic recirculation, allowing for once-daily or alternate-day dosing in maintenance therapy. Naloxone half-life is 1-2 hours. |
| Protein binding | Buprenorphine: Approximately 96% bound, primarily to alpha- and beta-globulins, and to a lesser extent albumin. Naloxone: Approximately 45% bound (mainly to albumin). |
| Volume of Distribution | Buprenorphine: Vd is 1.0-2.5 L/kg (mean ~1.8 L/kg), indicating extensive tissue distribution. Naloxone: Vd is 2.0-3.0 L/kg. |
| Bioavailability | Sublingual: 30-40% (range 15-50%) due to first-pass metabolism; buccal: approximately 30-50%. Intravenous bioavailability is 100% (not the intended route). Oral buprenorphine has poor bioavailability (<10%) due to extensive first-pass metabolism. |
| Onset of Action | Sublingual administration: Onset of clinical effect (analgesia, opioid blockade) occurs within 30-60 minutes (peak effect at 1-4 hours). Buccal administration: Similar onset. Intravenous (not approved but reported): Onset within minutes. |
| Duration of Action | Duration of opioid blockade and suppression of withdrawal symptoms is 24-48 hours (up to 72 hours at higher doses) due to high affinity and slow receptor dissociation. Duration of analgesia is 6-8 hours. Clinical note: Duration is dose-dependent; higher doses provide longer blockade. |
Sublingual, 2.9 mg/0.71 mg (buprenorphine/naloxone) once daily initially, titrated to maintenance of 5.7 mg/1.4 mg to 17.2 mg/4.2 mg once daily; maximum 17.2 mg/4.2 mg once daily.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment; use cautiously in severe renal impairment (CrCl <30 mL/min) due to potential accumulation, consider reducing dose or extending interval. |
| Liver impairment | Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce starting dose to 2.9 mg/0.71 mg sublingually once daily, titrate cautiously; Child-Pugh Class C: not recommended. |
| Pediatric use | Not approved for patients <16 years; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use with caution due to increased sensitivity, hepatic impairment, or concomitant medications; start at low end of dosing range. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZUBSOLV (ZUBSOLV).
| Breastfeeding | Buprenorphine excreted into breast milk in low concentrations; M/P ratio approximately 1.0 (range 0.7-1.9). Relative infant dose estimated 0.2-1.0% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding; monitor infant for drowsiness, respiratory depression, and feeding difficulties. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited data, but buprenorphine crosses placenta; risk of neural tube defects not significantly increased versus opioid-dependent untreated. Second trimester: No specific structural anomalies. Third trimester: Neonatal opioid withdrawal syndrome (NOWS) occurs in 40-60% of exposed neonates; risk of preterm birth and low birth weight. Overall, benefit of MAT outweighs risk of untreated opioid use disorder. |
■ FDA Black Box Warning
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISK OF OPIOID WITHDRAWAL WITH INADVERTENT INGESTION OR ABUSE. See full prescribing information for complete boxed warning.
| Serious Effects |
["Hypersensitivity to buprenorphine or naloxone","Significant respiratory depression","Acute or severe bronchial asthma","Known or suspected gastrointestinal obstruction","Patients with anticipated severe withdrawal or those who have not been adequately stabilized on buprenorphine monotherapy prior to induction"]
| Precautions | ["Addiction, abuse, and misuse","Life-threatening respiratory depression","Neonatal opioid withdrawal syndrome","Risks from concomitant use with benzodiazepines or other CNS depressants","Risk of opioid withdrawal with inadvertent ingestion or abuse","Hepatic impairment","Precipitation of opioid withdrawal","Adrenal insufficiency","QT prolongation"] |
Loading safety data…
| Fetal Monitoring | Maternal: liver function tests (LFTs) at baseline and periodically due to hepatotoxicity; respiratory rate and sedation level during dose titration; urine drug screens to monitor adherence and detect illicit use. Fetal: ultrasound for growth and anatomy; nonstress test or biophysical profile in third trimester for high-risk pregnancies; monitor for signs of NOWS after delivery using standardized scoring systems. |
| Fertility Effects | Buprenorphine may cause menstrual irregularities and disrupt hypothalamic-pituitary-gonadal axis, potentially reducing fertility; however, treatment of opioid use disorder can restore fertility. No specific teratogenicity on reproductive organs. |